Open AccessIntranasal lidocaine for acute migraine
Author(s) -
Pei Wen,
Kun Yi Hsieh,
Chien Wei Tsai,
Chin Wang Hsu,
Chyi Huey Bai,
Chiehfeng Chen,
Yuan Pin Hsu
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000015699
Subject(s) - medicine , migraine , acute migraine , lidocaine , cochrane library , placebo , medline , randomized controlled trial , adverse effect , visual analogue scale , guideline , headaches , intensive care medicine , anesthesia , alternative medicine , surgery , pathology , political science , law
Background: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. The aim of our study is to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of acute migraine. Methods: We will use PubMed, EMBASE, Cochrane library, and Scopus databases to search for articles from their inceptions to November 2018. We will only include randomized controlled studies. Data were independently will be extracted by 2 reviewers. Data analysis and synthesis will be analyzed by the Revman 5.3 software. We will conduct the study in accordance with the guideline of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. Results: This review will evaluate the efficacy and safety of intranasal lidocaine for acute migraine. The primary outcome is pain intensity measured by visual analogue, numerical rating scale, or verbal rating scale. Secondary outcomes are success rate, requirement of rescue medicine, relapse, and adverse events. Conclusion: The findings of this systematic review will summarize the latest evidence of intranasal lidocaine for acute migraine. The results will provide implications for clinical practice and further research. Prospero registration number: CRD42018116226